CliffBio
biologic

Nuwiq

Antihemophilic Factor (Recombinant)

Loss of exclusivityDecember 2033projected — 12-year biologic exclusivity estimate
CompanyOctapharma Pharmazeutika Produktionsges.m.b.H.

Drug detail

Brand nameNuwiq
Active ingredientAntihemophilic Factor (Recombinant)
Strength1500IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2021
Marketing statusRx

More from Octapharma Pharmazeutika Produktionsges.m.b.H.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Nuwiq patent cliff — loss of exclusivity December 2033 | CliffBio